Revised oral contraceptive labeling: FDA approves recommendation allowing delay of pelvic exam.
D000293:Adolescent; D000367:Age Factors; D000554:Ambulatory Care Facilities; D000569:Americas; D001519:Behavior; D003257:Consumer Product Safety; D003267:Contraception; D003276:Contraceptives, Oral; D003376:Counseling; D003710:Demography; D019049:Developed Countries; D003933:Diagnosis; D004467:Economics; D004644:Emotions; D005193:Family Planning Services; D005239:Fear; D006077:Government Agencies; D006285:Health Planning; D006297:Health Services Accessibility; D019359:Knowledge; D008389:Marketing of Health Services; D009656:North America; D009934:Organization and Administration; D009938:Organizations; D010808:Physical Examination; D011153:Population; D011154:Population Characteristics; D019064:Product Packaging; D011584:Psychology; D014481:United States
D003276:Contraceptives, Oral
Adolescents; Adolescents, Female; Age Factors; Americas; Behavior; Clinic Activities; Contraception; Contraceptive Availability; Contraceptive Methods; Counseling; Demographic Factors; Developed Countries; Economic Factors; Emotions; Examinations And Diagnoses; Family Planning; Fear; Government Agencies; Knowledge; Marketing; North America; Northern America; Oral Contraceptives; Organization And Administration; Organizations; Packaging; Physical Examinations And Diagnoses; Population; Population Characteristics; Product Approval; Program Activities; Programs; Psychological Factors; United States; Youth